NZ790800A - Anti-idiotypic antibodies against anti-cd19 antibodies - Google Patents
Anti-idiotypic antibodies against anti-cd19 antibodiesInfo
- Publication number
- NZ790800A NZ790800A NZ790800A NZ79080017A NZ790800A NZ 790800 A NZ790800 A NZ 790800A NZ 790800 A NZ790800 A NZ 790800A NZ 79080017 A NZ79080017 A NZ 79080017A NZ 790800 A NZ790800 A NZ 790800A
- Authority
- NZ
- New Zealand
- Prior art keywords
- cells
- antibodies
- idiotype antibodies
- specifically
- further relates
- Prior art date
Links
- 108010055216 Anti-Idiotypic Antibodies Proteins 0.000 title abstract description 8
- 108090001123 antibodies Proteins 0.000 title abstract description 8
- 102000004965 antibodies Human genes 0.000 title abstract description 8
- 210000004027 cells Anatomy 0.000 abstract description 9
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract description 6
- 102000005962 receptors Human genes 0.000 abstract description 6
- 108020003175 receptors Proteins 0.000 abstract description 6
- 210000001744 T-Lymphocytes Anatomy 0.000 abstract description 3
- 230000003213 activating Effects 0.000 abstract description 3
- 230000000694 effects Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 1
- 102000038129 antigens Human genes 0.000 description 1
- 108091007172 antigens Proteins 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
Abstract
Provided herein are anti-idiotype antibodies that specifically recognize anti-CD19 antibody moieties, in particular, anti-CD19 antibody moieties present in recombinant receptors, including chimeric antigen receptors (CARs). The disclosure further relates to uses of anti-idiotype antibodies for specifically identifying and/or selecting cells expressing such recombinant receptors, such as anti-CD19 CAR T cells. The disclosure further relates to uses of anti-idiotype antibodies for specifically activating such cells. fically identifying and/or selecting cells expressing such recombinant receptors, such as anti-CD19 CAR T cells. The disclosure further relates to uses of anti-idiotype antibodies for specifically activating such cells.
Description
ANTI-IDIOTYPIC ANTIBODIES AND RELATED METHODS
Cross-Reference to Related Applications
The application claims the t of priority to U.S. provisional patent application
,008, filed July 29, 2016, entitled “ANTIBODIES AND RELATED METHODS,” the
contents of which is hereby incorporated by reference in their entirety for all purposes.
Incorporation by Reference of Sequence Listing
The present application is being filed along with a Sequence Listing in electronic
format. The Sequence Listing is ed as a file entitled 735042006540SeqList.TXT, created
July 15, 2017 which is 86,050 bytes in size. The information in the electronic format of the
Sequence Listing is incorporated by reference in its entirety.
Field
The t disclosure relates in some aspects to anti-idiotype antibodies that
specifically recognize anti-CD19 antibody moieties, in particular, anti-CD19 antibody moieties
present in recombinant receptors, including chimeric antigen receptors (CARs). The disclosure
further relates to uses of diotype antibodies for specifically identifying or selecting cells
expressing such recombinant receptors, such as anti-CD19 CAR T cells. The disclosure further
relates to uses of anti-idiotype antibodies for specifically activating such cells.
Background
Methods are available for adoptive cell therapy using ered cells expressing
recombinant receptors, such as chimeric antigen receptor (CARs) containing extracellular
antibody antigen-binding domains. Various strategies are available to assess activity of such
cells either in vitro or upon in vivo to a subject. Improved s are needed to specifically
assess activity of CAR-expressing cells. Provided are reagents, compositions, and es of
cture that meet such needs.
sd-703489
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62/369,008 | 2016-07-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ790800A true NZ790800A (en) | 2022-08-26 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6680693A2 (en) | Recombinant human antibodies, both humanized and chimeric, which specifically bind human ox40 | |
| PH12020552138A1 (en) | Bcma chimeric antigen receptors and uses thereof | |
| Chu et al. | Prototypical type I E-cadherin and type II cadherin-7 mediate very distinct adhesiveness through their extracellular domains | |
| WO2018023100A3 (en) | Anti-idiotypic antibodies against anti-cd19 antibodies | |
| CR20190440A (en) | Improved antigen binding receptors | |
| TN2013000076A1 (en) | Anti-ox40 antibodies and methods of using the same | |
| AU2018260863A1 (en) | Human IgG1 Fc region variants and uses thereof | |
| MX2021013336A (en) | Antibodies and chimeric antigen receptors specific for cd19. | |
| Palani et al. | Stabilin‐1/CLEVER‐1, a type 2 macrophage marker, is an adhesion and scavenging molecule on human placental macrophages | |
| MX2021009151A (en) | Antibodies and chimeric antigen receptors specific for ror1. | |
| AR119683A1 (en) | ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS SPECIFIC TO ORPHAN RECEPTOR TYROSINE KINASE-LIKE 1 (ROR1) | |
| MY192682A (en) | Bispecific t cell engaging antibody constructs | |
| EP3593812A3 (en) | Treatment of cancer using chimeric antigen receptor | |
| MX2016007927A (en) | Tagged chimeric effector molecules and receptors thereof. | |
| WO2019089969A3 (en) | Antibodies and chimeric antigen receptors specific for b-cell maturation antigen | |
| MX2020009463A (en) | Il-13 receptor alpha 2 (il13ra2) chimeric antigen receptor for tumor specific t cell immunotherapy. | |
| MX2016008076A (en) | Human mesothelin chimeric antigen receptors and uses thereof. | |
| MX2020003046A (en) | Anti-hla-a2 antibodies and methods of using the same. | |
| EA201390847A1 (en) | APPLICATION OF MODIFIED T-CELLS WITH CHEMERIAL ANTIGEN RECEPTORS FOR THE TREATMENT OF MALIGNANT NOROVATION | |
| NZ601743A (en) | Methods for identifying and isolating cells expressing a polypeptide | |
| IN2014CN02906A (en) | ||
| EP3467101A3 (en) | Immunotherapy of brain tumor using geneticially engineered gd2-specific t cells | |
| MY150246A (en) | Alpha 5 - beta 1 antibodies and their uses | |
| Rizzo et al. | A simple method for identifying bone marrow mesenchymal stromal cells with a high immunosuppressive potential | |
| MX2021001771A (en) | Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating krebs cycle and therapeutic uses thereof. |